Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) is known to cure various hematological disorders; however, its widespread use is limited due to a lack of histocompatible donors. Reciprocal cell traffic between the mother and fetus during pregnancy gives rise to postpartum fetal-maternal lymphohematopoietic microchimerism, which is frequently detected in the blood or tissue of healthy individuals. Studies in clinical and experimental transplantation provide evidence that exposure to non-inherited maternal antigens (NIMAs) during pregnancy may result in long-lasting fetomaternal microchimerism and tolerance induction. Studies of HLA-mismatched HSCT have suggested a relatively lower incidence of severe graft-versus-host disease (GVHD) after transplantation from a NIMA-mismatched donor. Studies using a mouse model have also demonstrated a "child-to-mother" bone marrow transplantation from an NIMA-exposed donor to reduce the morbidity and mortality of GVHD in an antigen-specific manner while preserving the graft-versus- leukemia effects and favoring the immune reconstitution, thus resulting in a marked improvement in outcome after HSCT. Prospective clinical studies are therefore warranted to confirm these beneficial effects of fetal-maternal tolerance in allogeneic HSCT.
| Original language | English |
|---|---|
| Pages (from-to) | 165-172 |
| Number of pages | 8 |
| Journal | Archivum Immunologiae et Therapiae Experimentalis |
| Volume | 54 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Jun 2006 |
Fingerprint
Keywords
- GVHD
- HSCT
- Non-inherited maternal antigen
ASJC Scopus subject areas
- Immunology
Cite this
Impact of fetal-maternal tolerance in hematopoietic stem cell transplantation. / Teshima, Takanori; Matsuoka, Ken-ichi; Ichinohe, Tatsuo.
In: Archivum Immunologiae et Therapiae Experimentalis, Vol. 54, No. 3, 06.2006, p. 165-172.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Impact of fetal-maternal tolerance in hematopoietic stem cell transplantation
AU - Teshima, Takanori
AU - Matsuoka, Ken-ichi
AU - Ichinohe, Tatsuo
PY - 2006/6
Y1 - 2006/6
N2 - Allogeneic hematopoietic stem cell transplantation (HSCT) is known to cure various hematological disorders; however, its widespread use is limited due to a lack of histocompatible donors. Reciprocal cell traffic between the mother and fetus during pregnancy gives rise to postpartum fetal-maternal lymphohematopoietic microchimerism, which is frequently detected in the blood or tissue of healthy individuals. Studies in clinical and experimental transplantation provide evidence that exposure to non-inherited maternal antigens (NIMAs) during pregnancy may result in long-lasting fetomaternal microchimerism and tolerance induction. Studies of HLA-mismatched HSCT have suggested a relatively lower incidence of severe graft-versus-host disease (GVHD) after transplantation from a NIMA-mismatched donor. Studies using a mouse model have also demonstrated a "child-to-mother" bone marrow transplantation from an NIMA-exposed donor to reduce the morbidity and mortality of GVHD in an antigen-specific manner while preserving the graft-versus- leukemia effects and favoring the immune reconstitution, thus resulting in a marked improvement in outcome after HSCT. Prospective clinical studies are therefore warranted to confirm these beneficial effects of fetal-maternal tolerance in allogeneic HSCT.
AB - Allogeneic hematopoietic stem cell transplantation (HSCT) is known to cure various hematological disorders; however, its widespread use is limited due to a lack of histocompatible donors. Reciprocal cell traffic between the mother and fetus during pregnancy gives rise to postpartum fetal-maternal lymphohematopoietic microchimerism, which is frequently detected in the blood or tissue of healthy individuals. Studies in clinical and experimental transplantation provide evidence that exposure to non-inherited maternal antigens (NIMAs) during pregnancy may result in long-lasting fetomaternal microchimerism and tolerance induction. Studies of HLA-mismatched HSCT have suggested a relatively lower incidence of severe graft-versus-host disease (GVHD) after transplantation from a NIMA-mismatched donor. Studies using a mouse model have also demonstrated a "child-to-mother" bone marrow transplantation from an NIMA-exposed donor to reduce the morbidity and mortality of GVHD in an antigen-specific manner while preserving the graft-versus- leukemia effects and favoring the immune reconstitution, thus resulting in a marked improvement in outcome after HSCT. Prospective clinical studies are therefore warranted to confirm these beneficial effects of fetal-maternal tolerance in allogeneic HSCT.
KW - GVHD
KW - HSCT
KW - Non-inherited maternal antigen
UR - http://www.scopus.com/inward/record.url?scp=33747457056&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33747457056&partnerID=8YFLogxK
U2 - 10.1007/s00005-006-0018-y
DO - 10.1007/s00005-006-0018-y
M3 - Article
C2 - 16652218
AN - SCOPUS:33747457056
VL - 54
SP - 165
EP - 172
JO - Archivum Immunologiae et Therapiae Experimentalis
JF - Archivum Immunologiae et Therapiae Experimentalis
SN - 0004-069X
IS - 3
ER -